By Adam L. Cataldo
FibroBiologics Chief Financial Officer Mark Andersen has resigned to pursue other opportunities, the company said.
Andersen informed the biotechnology company of his decision on Oct. 25, according to a filing Tuesday with the Securities and Exchange Commission. His resignation will become effective when a new or interim CFO is appointed, or on his date of resignation, Nov. 15, whichever comes first.
Andersen will remain employed as CFO, but will no longer have the powers, duties and responsibilities that come with the position. His main responsibility will be to transition his duties and knowledge to his successor, the company said.
Write to Adam Cataldo at adam.cataldo@wsj.com
(END) Dow Jones Newswires
October 29, 2024 19:38 ET (23:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.